Drug Designing against Heterogeneous Targets, Cell, Heterogeneity, Human Immunodeficiency Virus, HIV, Indianavir, Nelfinavir

Scholarships Dictionary Visa Details Study Abroad Exam Results Online Test Jobs

	Home
Drug Discovery and Drug Designing Drug Discovery and Drug Designing Introduction Early History of Drug Discovery History of Drug Discovery Enzymes/Receptors as Drug Targets Receptors as Drug Targets Enzymes as Drug Targets Molecular Biology for Drug Discovery Recombinant Proteins and Monoclonal Antibodies as Drugs Molecular basis of Disease Processes Target Identification and Validation Combinatorial Chemistry and HTS Organic Synthesis (Combinatorial Chemistry for Drug Discovery) Target-Oriented Organic Synthesis and Retrosynthetic Analysis

Home >> Industrial and Microbial Biotechnology >>Drug Discovery and Drug Designing >> Drug Designing Against Heterogeneous Targets

Your Ad Here

Drug designing against heterogeneous targets

Heterogeneity exists in the same target protein in the cell and leads to lower efficacy and safety. Therefore, that can accommodate the variation, which occur in nature. The heterogeneity, therefore, is integrated into the drug design process. The human immunodeficiency virus and is represented by several subtypes (A.B,C). For HIV-1, the first-generation protease inhibitors (Indianavir, Nelfinavir, Ritonavir and Saquinavir) had relatively unfavourable enthalpies, requiring very high entropy. The situation is reverse with second generation inhibitors, which had highly favourable enthalpies, but low binding entropies; they exhibited binding affinity higher than that of the first generation inhibitors.

	Home
Diversity-Oriented Organic Synthesis and Evolving Synthetic Analysis Solid Phase Synthesis for Drug Discovery Combinatorial Biocatalysis for Drug Disovery Synthesis of Bergenin Derivatives Drug Discovery in Cancer Research Microbial Genomics for New Antibiotics Genomics Drugs (Pharmacogenomics) Immunotoxins as Drugs Drug Designing Drug Designing by Blocking Enzyme Activity Drug Designing through Blocking Hormone Receptors Drug Designing through Inhibition of Nucleic Acid Synthesis Drug Designing Against Heterogeneous Targets